1.3-Di-O--glycerol | 17459-83-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1.3-Di-O--glycerol
• 英文别名: Desacylcardiolipin；1,3-Diglycerophosphoryl-glycerin；1,3-bis-[(2,3-dihydroxy-propoxy)-hydroxy-phosphoryloxy]-propan-2-ol；phosphoric acid O,O'''-(2-hydroxy-propane-1,3-diyl) ester O',O''''-bis-(2,3-dihydroxy-propyl) ester；Bis(glycerophospho)glycerol；[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] 2,3-dihydroxypropyl hydrogen phosphate
• CAS: 17459-83-5
• 化学式: C₉H₂₂O₁₃P₂
• 分子量: 400.213
• InChiKey: RCBRFGAYXGRKBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.5
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  213
• 氢给体数：
  7
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  2-苄氧基-1,3-丙二醇 、 phosphoric acid mono-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl) ester 生成 1.3-Di-O--glycerol
  参考文献：
  名称：

  Plackett,P., Australian Journal of Chemistry, 1964, vol. 17, p. 101 - 108

  摘要：

  DOI：

文献信息

• CARBOXYLIC ACID-TYPE LIPID, AND LIPID PARTICLE AND LIPID MEMBRANE EACH COMPRISING CARBOXYLIC ACID-TYPE LIPID
  申请人：Toray Industries, Inc.

  公开号：US20210387943A1

  公开（公告）日：2021-12-16

  A carboxylic acid-type lipid can accelerate adhesion or aggregation of platelets even if the carboxylic acid-type lipid does not carry a protein involved in adhesion or aggregation of platelets or a peptide corresponding to an active site of the protein; a lipid particle and a lipid membrane each include the carboxylic acid-type lipid; and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane. A carboxylic acid-type lipid is selected from carboxylic acid-type lipids represented by formulas (I) to (VI), a lipid particle includes the carboxylic acid-type lipid, a lipid membrane includes the carboxylic acid-type lipid, and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane.

  一种羧酸型脂质即使不携带与血小板粘附或聚集有关的蛋白质或相应的蛋白质活性位点对血小板的粘附或聚集也能加速，脂质颗粒和脂质膜均包括该羧酸型脂质；血小板聚集加速剂、血小板粘附加速剂、止血剂和血小板替代物均包括该羧酸型脂质、脂质颗粒或脂质膜。所述羧酸型脂质选自公式（I）到（VI）所表示的羧酸型脂质，脂质颗粒包括该羧酸型脂质，脂质膜包括该羧酸型脂质，血小板聚集加速剂、血小板粘附加速剂、止血剂和血小板替代物均包括该羧酸型脂质、脂质颗粒或脂质膜。
• HEMOSTATIC MATERIAL
  申请人：Toray Industries, Inc.

  公开号：US20220096707A1

  公开（公告）日：2022-03-31

  A hemostatic material includes a lipid that can accelerate adhesion or aggregation of platelets even if the lipid does not carry a protein or a peptide involved in adhesion or aggregation of platelets such as GPIb and H12 and, to achieve the object, provides a hemostatic material including a water-insoluble base and a lipid supported on a surface of the base, wherein the lipid includes one or two or more anionic lipids.
• PHARMACEUTICAL COMPOSITIONS FOR CLINICAL NUTRITION
  申请人：BAXTER INTERNATIONAL INC.

  公开号：US20220395516A1

  公开（公告）日：2022-12-15

  The present disclosure relates to a pharmaceutical composition for providing phosphorus to an adult or pediatric patient, wherein the composition is an aqueous solution of sodium glycerophosphate which by virtue of an improved process for producing the active pharmaceutical ingredient and the pharmaceutical composition is characterized by a low amount of free phosphate, a low amount of SGP-related substances and by a low amount of aluminum. The pharmaceutical composition is used in clinical nutrition, preferably in the preparation of nutritional formulations by compounding. The compositions can further be used for preventing or correcting phosphorus deficiency (hyperphosphatemia) in said adult or pediatric patients.